Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
AVAILABLE
NCT03720626
Managed Access Programs for SEG101, Crizanlizumab
Sponsor: Novartis Pharmaceuticals
View on ClinicalTrials.gov
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab
Key Details
Gender
All
Age Range
12 Years - 70 Years
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-04-14
Healthy Volunteers
No
Conditions
Interventions
DRUG
crizanlizumab
Patients receive crizanlizumab